Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Recruiting 4

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 165Sarcoma 37Gastrointestinal 12Thoracic 9Dermatologic 9Lymphoid 7Endocrine 7Genitourinary 5Tumor-Agnostic 4NET 3Breast 3Gynecologic 2Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Neoplasms 3Neoplasm Metastasis 1

Interventions

pembrolizumab 56Specimen Handling 28Biopsy 27Magnetic Resonance Spectroscopy 26Paclitaxel 22Blood Specimen Collection 21Nivolumab 20atezolizumab 18Standard of Care 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 17Oxaliplatin 13Fluorouracil 13Cisplatin 13Radiotherapy 12Radiosurgery 12Cyclophosphamide 12Pemetrexed 11Leucovorin 11Irinotecan 10Gemcitabine 10Docetaxel 10Capecitabine 10trastuzumab deruxtecan 8olaparib 8Taxes 8Ipilimumab 8durvalumab 7Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Temozolomide × Tumor-Agnostic × 1 year × Clear all
NCT05004116 2026-06-04

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Recruiting
77 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03899155 2026-06-03

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting
1,500 enrolled
Tumor-Agnostic

Neoplasms

NCT05999994 2026-03-27

CAMPFIRE

Eli Lilly and Company

Phase 2 Recruiting
105 enrolled
Tumor-Agnostic

Neoplasms

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡